Predict your next investment

Corporation
HEALTHCARE | Drug Development
euthymics.com

See what CB Insights has to offer

Stage

Acquired

Total Raised

$28.33M

Investors Count

7

Deal Terms

2

Portfolio Exits

1

Euthymics Bioscience Funding, Euthymics Bioscience Valuation & Euthymics Bioscience Revenue

5 Fundings

Euthymics Bioscience's latest funding round was a Acquired for on November 1, 2017.

Euthymics Bioscience's valuation in July 2010 was $24.89M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/1/2017

Acquired

$0.00B

((9.99x))

FY 1234

1

6/1/2017

Unattributed

$99M

$0.00B

((9.99x))

FY 1234

10

5/30/2012

Series A - III

$99M

$0.00B

((9.99x))

FY 1234

10

3/9/2011

Series A - II

$99M

$0.00B

((9.99x))

FY 1234

10

7/16/2010

Series A

$99M

$24.89M

$0.00B

((9.99x))

FY 1234

10

Date

11/1/2017

6/1/2017

5/30/2012

3/9/2011

7/16/2010

Round

Acquired

Unattributed

Series A - III

Series A - II

Series A

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$24.89M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

1

10

10

10

10

Euthymics Bioscience Deal Terms

2 Deal Terms

Euthymics Bioscience's deal structure is available for 2 funding rounds, including their Series A - III from May 30, 2012.

Round

Series A - III

Series A

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A - III

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

Euthymics Bioscience Investors

7 Investors

Euthymics Bioscience has 7 investors. Ethismos Research invested in Euthymics Bioscience's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/1/2017

11/1/2017

1
Acquired

Corporation

Massachusetts

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Asset/Investment Management

Massachusetts

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporate Venture

Switzerland

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Australia

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Wisconsin

First funding

11/1/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

11/1/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Corporation

Asset/Investment Management

Corporate Venture

Venture Capital

Venture Capital

Location

Massachusetts

Massachusetts

Switzerland

Australia

Wisconsin

Euthymics Bioscience Acquisitions

1 Acquisition

Euthymics Bioscience acquired 1 company. Their latest acquisition was Neurovance on January 01, 2011.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/1/2011

Debt

$35.02M

Spinoff / Spinout

1

Date

1/1/2011

Investment Stage

Debt

Companies

Valuation

Total Funding

$35.02M

Note

Spinoff / Spinout

Sources

1

Euthymics Bioscience Portfolio Exits

1 Portfolio Exit

Euthymics Bioscience has 1 portfolio exit. Their latest portfolio exit was Neurovance on March 02, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/2/2017

Acquired

$991

3

Date

3/2/2017

Exit

Acquired

Companies

Valuation

$991

Acquirer

Sources

3

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.